NEW_CURA-LEAF_1170x120_OCT

David Silverman

Outlook: New landscape for drug chains?

Outlook: New landscape for drug chains?

NEW YORK — Entering the second quarter of 2017, the chain drug industry was awaiting answers to a couple of big, lingering questions. First, what will the chain drug landscape look like? A significant change in the field of players is likely in store pending antitrust clearance of Walgreens Boots Alliance Inc.’s (WBA’s) deal to